Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 1
2000 1
2003 1
2009 1
2010 1
2011 2
2012 1
2013 1
2016 1
2020 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Guideline adherence in ovarian cancer for surgical staging in the Netherlands.
Baldewpersad Tewarie NMS, van Ham M, Wouters M, Kruitwagen R, van Driel W; participants of the Dutch Gynecological Oncology Collaborator Group; participants of the Dutch Gynecological Oncology Collaborator Group. Baldewpersad Tewarie NMS, et al. Int J Gynecol Cancer. 2022 Dec 5;32(12):1592-1598. doi: 10.1136/ijgc-2022-003666. Int J Gynecol Cancer. 2022. PMID: 36270772
Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
Algera MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, Wouters MWJM; participants of the Dutch Gynecological Oncology Collaborator group. Algera MD, et al. Gynecol Oncol. 2022 May;165(2):330-338. doi: 10.1016/j.ygyno.2022.02.013. Epub 2022 Feb 22. Gynecol Oncol. 2022. PMID: 35221132 Free PMC article.
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group. Vos JR, et al. J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080. J Natl Cancer Inst. 2020. PMID: 31076742 Free PMC article.
Efficacy of a regional network for ovarian cancer care.
van Altena AM, van den Akker PA, de Hullu JA, Ottevanger PB, Aalders AL, Gerritse R, Happel M, Hoekstra MP, Janssen MJ, Samlal RA, Smeets KM, Snijders MP, Vasmel MJ, Vollebergh JH, Kiemeney LA, Massuger LF. van Altena AM, et al. Among authors: aalders al. Obstet Gynecol. 2013 Sep;122(3):668-75. doi: 10.1097/AOG.0b013e3182a054ee. Obstet Gynecol. 2013. PMID: 23921868
Clinical auditing as an instrument to improve care for patients with ovarian cancer: The Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group. Baldewpersad Tewarie NMS, et al. Eur J Surg Oncol. 2021 Jul;47(7):1691-1697. doi: 10.1016/j.ejso.2021.01.019. Epub 2021 Feb 5. Eur J Surg Oncol. 2021. PMID: 33581966 Free article.
Case-mix adjustment to compare hospital performances regarding complications after cytoreductive surgery for ovarian cancer: a nationwide population-based study.
Algera MD, Baldewpersad Tewarie NMS, Driel WJV, van Ham MAPC, Slangen BFM, Kruitwagen RFPM, Wouters MWJM; Participants of the Dutch Gynecological Oncology Audit Collaborator Group. Algera MD, et al. Int J Gynecol Cancer. 2023 Apr 3;33(4):534-542. doi: 10.1136/ijgc-2022-003981. Int J Gynecol Cancer. 2023. PMID: 36581486
Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group. Baldewpersad Tewarie NMS, et al. Gynecol Oncol. 2021 Aug;162(2):331-338. doi: 10.1016/j.ygyno.2021.05.030. Epub 2021 Jun 17. Gynecol Oncol. 2021. PMID: 34147284 Free article.
Factors influencing the use of frozen section analysis in adnexal masses.
van den Akker PAJ, Kluivers KB, Aalders AL, Snijders MPLM, Samlal RAK, Vollebergh JHA, Zusterzeel PLM, Massuger LFAG. van den Akker PAJ, et al. Among authors: aalders al. Obstet Gynecol. 2011 Jul;118(1):57-62. doi: 10.1097/AOG.0b013e318220f047. Obstet Gynecol. 2011. PMID: 21691163
External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses.
van den Akker PA, Zusterzeel PL, Aalders AL, Snijders MP, Samlal RA, Vollebergh JH, Kluivers KB, Massuger LF. van den Akker PA, et al. Among authors: aalders al. Eur J Obstet Gynecol Reprod Biol. 2011 Dec;159(2):422-5. doi: 10.1016/j.ejogrb.2011.07.035. Epub 2011 Aug 6. Eur J Obstet Gynecol Reprod Biol. 2011. PMID: 21824712 Free article.
17 results